Last reviewed 2026-04-20 · How we verify

PF-04449913 (pf-04449913)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nausea
• Anaemia
• Diarrhoea
• Febrile neutropenia
• Constipation
• Pyrexia
• Platelet count decreased
• Hypokalaemia
• Dysgeusia
• Thrombocytopenia
• Vomiting
• White blood cell count decreased

Key clinical trials

• Molecular Profiling of Advanced Soft-tissue Sarcomas (PHASE3)
• A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies (PHASE1)
• Glasdegib for Chronic Graft-Versus-Host Disease (PHASE1, PHASE2)
• A Study Of PF-04449913 In Select Hematologic Malignancies (PHASE1)
• Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma (PHASE1, PHASE2)
• A Study Of PF-04449913 Administered Alone In Select Solid Tumors (PHASE1)
• A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients (PHASE1)
• Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.